Breakdown |
---|
Income Statement |
Total Revenue |
Gross Profit |
EBITDA |
Net Income |
Balance Sheet |
Total Assets |
Cash, Cash Equivalents and Short-Term Investments |
Total Debt |
Total Liabilities |
Stockholders Equity |
Cash Flow |
Free Cash Flow |
Operating Cash Flow |
Investing Cash Flow |
Financing Cash Flow |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
65 Neutral | $474.97M | ― | -2.91% | ― | -1.86% | -2.01% | |
59 Neutral | $262.86M | ― | -44.97% | ― | 21.06% | -99.70% | |
57 Neutral | £4.92B | 6.91 | -62.36% | 2.24% | 34.00% | 6.32% | |
53 Neutral | $492.14M | ― | -177.29% | ― | -23.99% | -100.40% | |
50 Neutral | $479.74M | ― | -29.16% | ― | 25.77% | 49.44% | |
47 Neutral | $183.03M | ― | -52.87% | ― | -4.16% | 12.79% | |
47 Neutral | $172.79M | ― | 271.41% | ― | 85.03% | 53.73% |
On June 18, 2025, Cytek Biosciences held its annual meeting of stockholders, with approximately 81.4% of outstanding shares represented. During the meeting, Richard Chin, MD, and Deborah Neff were elected as Class I directors to serve until 2028. Additionally, the executive compensation for 2024 was approved, and Deloitte & Touche LLP was ratified as the independent registered public accounting firm for 2025.
The most recent analyst rating on (CTKB) stock is a Buy with a $8.25 price target. To see the full list of analyst forecasts on Cytek Biosciences stock, see the CTKB Stock Forecast page.